Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Bhavya S. Doshi"'
Autor:
Bhavya S. Doshi, Benjamin J. Samelson-Jones, Timothy C. Nichols, Elizabeth P. Merricks, Joshua L. Siner, Robert A. French, Ben J. Lee, Valder R. Arruda, Mary Beth Callan
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 32, Iss 1, Pp 101205- (2024)
The hemophilias are the most common severe inherited bleeding disorders and are caused by deficiency of clotting factor (F) VIII (hemophilia A) or FIX (hemophilia B). The resultant bleeding predisposition significantly increases morbidity and mortali
Externí odkaz:
https://doaj.org/article/b7c59031eecd4b9ca3b2c7a6fcb6f7d7
Autor:
Lucas Van Gorder, Bhavya S. Doshi, Elinor Willis, Timothy C. Nichols, Emma Cook, John K. Everett, Elizabeth P. Merricks, Valder R. Arruda, Frederic D. Bushman, Mary Beth Callan, Benjamin J. Samelson-Jones
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 31, Iss , Pp 101159- (2023)
Adeno-associated viral (AAV) vectors have traditionally been viewed as predominantly nonintegrating, with limited concerns for oncogenesis. However, accumulating preclinical data have shown that AAV vectors integrate more often than previously apprec
Externí odkaz:
https://doaj.org/article/c962f9d134214b5e82348ed40acae6dc
Publikováno v:
F1000Research, Vol 7 (2018)
Several new therapies for hemophilia have emerged in recent years. These strategies range from extended half-life factor replacement products and non-factor options with improved pharmacokinetic profiles to gene therapy aiming for phenotypic cure. Wh
Externí odkaz:
https://doaj.org/article/2f328eb1aaa84f4e8e5929c68ea5fcb2
Autor:
Allyson M Pishko, Bhavya S Doshi
Publikováno v:
Journal of Blood Medicine. 13:255-265
In acquired hemophilia A (AHA), autoantibodies to coagulation factor VIII (FVIII) neutralize FVIII activity leading to a potentially severe bleeding diathesis that carries a high rate of morbidity and mortality. This disorder is rare and occurs mainl
Autor:
Lucas Van Gorder, Bhavya S. Doshi, Elinor Willis, Matthew Lanza, Valder R. Arruda, Mary Beth Callan, Ben J. Samelson-Jones
Publikováno v:
Blood. 140:4919-4920
Autor:
Bhavya S Doshi, Ben J Samelson-Jones, Timothy C Nichols, Elizabeth P Merricks, Valder R Arruda, Mary Beth Callan
Publikováno v:
Blood. 140:7780-7781
Publikováno v:
Journal of Pediatric Hematology/Oncology. 44:261-263
Hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency varies by mutation status and the oxidative stressor. Although classified by percent of enzymatic deficiency, variability in normal G6PD values clouds assessment of hemolysis risk by le
Publikováno v:
J Thromb Haemost
Background Hemophilia A (HA) inhibitor patients that fail traditional immune tolerance induction (ITI) have increased morbidity and mortality. Preclinical studies support factor VIII (FVIII) tolerance induction with a combined approach of anti-CD20 m
Autor:
Angela M. Ellison, Bhavya S Doshi
Publikováno v:
Pediatric emergency care. 37(5)
The incidence of venous thromboembolism (VTE) is increasing in pediatric patients. Prompt recognition and evaluation of VTE in young patients could prevent significant morbidity or mortality. In contrast to VTE in adults, current treatment guidelines
Autor:
Bhavya S. Doshi, Radoslaw Kaczmarek, Valder R. Arruda, Cindy A. Leissinger, John S.S. Butterfield, Giancarlo Castaman, Moanaro Biswas, Shannon L. Meeks, Mostafa A. Shaheen, Jyoti Rana
Publikováno v:
The Journal of Clinical Investigation
Inhibitors of factor VIII (FVIII) remain the most challenging complication of FVIII protein replacement therapy in hemophilia A (HA). Understanding the mechanisms that guide FVIII-specific B cell development could help identify therapeutic targets. T